Leishmania

Resistance to Miltefosine Associated with Genetic Marker
To the Editor: During 2000-2010, serial Leishmania isolates obtained from an HIV-infected patient who was not responding to treatment showed a gradual decrease in in vitro miltefosine susceptibility. We performed L. donovani miltefosine transporter (Ldmt) gene analysis to identify an association between miltefosine resistance of reference L. donovani lines and variability in miltefosine response of L. infantum isolates. A new single-nucleotide polymorphism (SNP), L832F, was identifi ed, which might be a marker of miltefosine resistance in leishmaniasis.
The patient, a 46-year-old woman, had lived in France since 1994 but regularly returned to Algeria, her country of birth. HIV-1 infection was diagnosed in 1991. Antiretroviral therapy was initiated in 1993, leading to undetectable viral load and a CD4+ T-cell count of 185 cells/mm 3 (reference >450/mm 3 (Table) .
The susceptibility of 4 cryopreserved isolates (S 1 , S 3 , S 4 , and S 6 ; Table) to AmpB and to miltefosine was studied in the in vitro promastigote and axenic amastigote form by determining the concentrations inhibiting parasite growth by 50% (1, 2) . The 50% inhibitory concentration (IC 50 ) was determined in parallel for the following reference L. donovani
, a laboratory miltefosine-resistant line obtained from LV9 WT (LV9 miltefosine-R, resistant to 90 μmol/L miltefosine), and the laboratory AmBresistant line obtained from DD8 WT (DD8 AmB-R, resistant to 1.4 μmol/L AmB) on promastigote and axenic amastigote forms (3, 4) .
The AmB susceptibility of the isolates did not change notably over time; IC 50 values ranged from 0.09 μmol/L to 0.24 μmol/L, regardless of parasite form, similar to those of wild-type reference strains (Table) . In contrast, the IC 50 values of miltefosine increased greatly over time, from 5.00 μmol/L to 50.10 μmol/L. During the 6 years of follow-up with miltefosine maintenance therapy, the susceptibility of the isolate (S 6 ) obtained 6 months after miltefosine treatment withdrawal in 2008 was 6-fold higher than that of the fi rst isolate (S 1 ) obtained in 2000.
The L. donovani miltefosine transporter protein (LdMT) promotes miltefosine translocation (5), and LdMT inactivation in L. donovani promastigotes leads to miltefosine resistance at the promastigote and amastigote stages (6) . In 2003 and 2006 studies, several mutations were linked to the inability of parasites to take up miltefosine and to miltefosine resistance (5, 7) . In a 2009 study, the weak expression of LdMT and its β subunit LdROS3 in L. braziliensis isolates was linked to diminished sensitivity (8) . We sequenced the entire Ldmt gene (3,294 bp) in the reference strains and the clinical isolates for SNP analysis (5,7). Only 1 new SNP, L832F, was found in the miltefosine-resistant reference strain (LV9 miltefosine-R) and in clinical isolate S 6 . The L832 wild-type allele was found in isolate S 1 and in the miltefosine-sensitive reference lines (LV9, DD8, and DD8 AmpB-R), whereas both alleles were found in isolates S 3 and S 4 , with a decrease in the wild-type allele (Table) . The last isolate, which was obtained 3 years after miltefosine withdrawal and could not be subcultured, had reverted to the wild-type allele (L832).
These results point to a relation between the 832F allele and diminished susceptibility to miltefosine. Analysis of this case of miltefosine resistance in a patient co-infected with Leishmania sp. and HIV strongly suggests that an SNP (L832F) in the Ldmt gene could represent a molecular marker of miltefosine resistance in L. infantum and L. donovani. 
Prolonged KI Polyomavirus Infection in Immunodefi cient Child
To the Editor: Two novel polyomaviruses (PyVs), KIPyV and WUPyV, were identifi ed in respiratory and fecal specimens from children with signs and symptoms of respiratory tract infection (1, 2) . A review of literature on emerging viruses in transplant recipients indicated that up to 80% of patients harboring these PyVs are coinfected with another respiratory virus, complicating interpretation of positive fi ndings (3). Seroprevalence of KIPyV and WUPyV in healthy blood donors in Germany have been reported to be 67% and 89%, respectively (4).
The effect of these viruses in immunocompromised patients is unknown. Some studies report a higher frequency of KIPyV DNA detection in hematopoietic stem cell transplant (HSCT) recipients (5-7) than in immunocompetent patients. In fact, HCST recipients might be more prone to productive infection with KIPyV and WUPyV than to infection with PyVs JC and BK (BKPyV) (5) .
We report prolonged detection of KIPyV DNA in the respiratory tract of an immunocompromised child. A 12-year-old girl with severe combined immunodefi ciency was admitted to the Freiburg University Medical Center, Germany, in November 2009 for treatment of progressive respiratory problems and cytomegalovirus (CMV) disease. Although the molecular basis of the immune disorder was unknown, HSCT was indicated because of uncontrolled CMV infection and progressive clinical deterioration.
Allogenic HSCT was performed in February 2010. Pretransplant treatments included thyothepa (day −7; 8 mg/kg), fl udarabine (days −6 to −3; 120 mg/m 2 ), treosulfan (days -6 to -4; 42 g/m 2 ), and antithymocyte globulin (days −4 to −2; 45 mg/kg). The patient received bone marrow cells (4.2 × 10 6 CD34-positive cells/ kg) from an 8/10 human leukocyte antigen-matched, CMV-positive, unrelated donor. Graft-versus-host disease prophylaxis consisted of cyclosporine A (from day −1) and methotrexate (days +1, +3, +6; 10 mg/m 2 ). Leukocyte, granulocyte, and platelet engraftment occurred on days +18, +19, and +32, respectively. Full donor chimera was detected by day +62 (Figure, panel A) .
Before hospitalization, the child had had several pulmonary infections. At admission, chest radiograph showed middle lobe atelectasis but no visible infi ltrates. On day −83, human bocavirus was detected. On day −27, the occurrence of bilateral infi ltrates was assessed, and pneumonia was diagnosed. On day +55, fever and hypoxia were monitored; chest radiograph revealed regressive infi ltrates in the lower lobes but central infi ltrates in the upper lobes. Rhinovirus RNA was detected at this time and persisted in the respiratory tract until day +98 (Figure, panel  A) . Retrospectively, KIPyV DNA was detected in 6 nasopharyngeal aspirate specimens, 4 throat swab specimens, and 1 bronchoalveolar lavage specimen collected between days −103 and +98 (Figure, panel B) . No KIPyV was detected in EDTAtreated blood samples at any time. Stool samples were not available. The highest level of KIPyV DNA (10 9 copies/mL) was detected on day +16. Starting from day +43, a steady decrease in KIPyV viral load was observed. Phenotypical analysis of blood leukocytes on day +55 showed normal CD56+/16+ natural killer cells and good T-cell engraftment but no B cells. On day +108, viral clearance had occurred. Sequencing of the small t antigen amplifi ed from all available samples was performed (8) and showed 100% nucleotide identity (GenBank accession no. JN874415).
